Plus Therapeutics Advances CNS Cancer Diagnostics Toward Reimbursement-Driven Growth
Plus Therapeutics’ (NASDAQ: PSTV) diagnostic subsidiary, CNSide, has cleared an important hurdle to unlock U.S. government reimbursement, gaining the regulatory footing needed to enroll in Medicare and Medicaid as it expands access to its CNS cancer testing. For a thinly traded micro‑cap like Plus Therapeutics, this kind of payor progress can be an early building block for future revenue and broader adoption of its CNSide platform.
What Medicare enrollment means
CNSide Diagnostics, Plus Therapeutics’ wholly owned lab business, previously secured CLIA accreditation from the Centers for Medicare & Medicaid Services (CMS), a mandatory step for labs that want to enroll in Medicare and Medicaid and get paid for testing services. That accreditation, combined with ongoing work on coding and contracting, is intended to open up reimbursement from both government and commercial payors for the company’s cerebrospinal fluid (CSF) tumor cell enumeration test used in central nervous system cancers.
Alongside Medicare/Medicaid enrollment efforts, CNSide has already landed a national coverage agreement with UnitedHealthcare that gives more than 51 million covered lives potential access to its CNS cancer diagnostic test across the U.S. This combination of lab accreditation, coverage policy, and payment coding work is central to turning a novel test into a scalable commercial service.
Why it matters for PSTV
For PSTV, expanded reimbursement is critical to unlocking more consistent diagnostic revenue that can help support its broader radiotherapeutics pipeline. As CNSide adds payor contracts, proprietary lab codes, and Medicare/Medicaid enrollment, each incremental step can increase physician uptake, repeat testing, and overall utilization of the platform.
Investors should watch for concrete updates on Medicare and Medicaid enrollment status, additional payor deals, and procedure volumes, as well as parallel milestones like the new Category III CPT code for REYOBIQ and progress in ongoing brain cancer trials, all of which shape the longer‑term value story for Plus Therapeutics.
